ClinicalTrials.gov
ClinicalTrials.gov Menu

Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00240344
Recruitment Status : Completed
First Posted : October 18, 2005
Last Update Posted : August 30, 2011
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
The purpose of this study is to determine the efficacy of Crestor in high risk patients switched from higher doses of other statins in obtaining the new European Atherosclerosis Society (EAS) low-density lipoprotein cholesterol (LDL-C) guidelines.

Condition or disease
Hypercholesterolemia

Study Type : Observational
Actual Enrollment : 2650 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: REALISTIC: Protocol for an Observational Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New EAS LDL-C Target Goal
Study Start Date : September 2004
Actual Primary Completion Date : February 2008
Actual Study Completion Date : February 2008






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
primary care
Criteria

Inclusion Criteria:

  • High risk patients
  • High doses of other statins
  • LDL-C known, starts with Crestor 10 mg
  • Permission to use patient data by AstraZeneca (AZ)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00240344


  Show 75 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: AstraZeneca Netherlands Medical Director, MD AstraZeneca

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00240344     History of Changes
Other Study ID Numbers: NL401142
REALISTIC
First Posted: October 18, 2005    Key Record Dates
Last Update Posted: August 30, 2011
Last Verified: August 2011

Keywords provided by AstraZeneca:
High risk patients
Crestor
Rosuvastatin
LDL cholesterol
observational

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors